Obtenga las últimas noticias sobre las acciones de GRAIL con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de GRAL

Últimas noticias sobre

GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

Volatilidad

Media

MRNA

Volatilidad y nerviosismo sacuden los mercados por las políticas comerciales impredecibles de Trump. ¿Qué podría pasar ahora?

Analistas advierten impacto financiero si Trump no redefine su estrategia comercial pronto

GRAIL Inc

GRAIL INC COM

Press Releases

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC

Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's Galleri® Multi-Cancer Early Detection Test to Asia

Opinion

Precision Oncology Approaches Drive $312B Market Transformation

GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings

/U P D A T E -- GRAIL, Inc./

GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)

GRAIL, Inc. Announces $325.0 Million Private Placement Financing

GRAIL to Announce Third Quarter 2025 Financial Results

CCCC

GTBP

NRIX

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Cidara Therapeutics

Celcuity

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Dyne Therapeutics

Amicus Therapeutics

IDEAYA Biosciences

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

Canaccord Genuity

Morgan Stanley

Comments

GRAIL Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL